Invivyd Inc. (IVVD) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Invivyd Inc. stock $0.61, price $0.56, upside +8.7%, quality 41 out of 100. Rating: fairly valued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range $0.3580 – $56.08 · fair‑value band $0.3995 – $0.7650 · the $0.5630 price screens below the $0.6120 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Invivyd in your weekly email
Every Wednesday you see whether Invivyd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States.
Show moreShow less
The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children.
It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022.
Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.
Stock analysis
Invivyd Inc. (IVVD) currently trades at $0.5630, while our model-based Fair Value estimate is $0.6120, so the stock looks roughly fairly valued today (gap 8.0%).
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.3995 (bear) to $0.7650 (bull), the price of $0.5630 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Invivyd Inc. reported revenue of $53.4M in FY2025 versus $0 in FY2021. Reported net income was −$52.5M in FY2025.
Key figures
Market cap $180M Micro · P/S ratio 2.84 · EPS (TTM) $−0.3300 · Net margin −98.2% · Return on equity −95.9% · Return on assets (EBIT) −70.2% (5-year average) · Operating margin −321% · Revenue (TTM) $58.4M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).
What moves the price
The share trades about 80% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 9%, IVVD screens richer than that median.
Fair Value models
Bear$0.3995Fair Value $0.6120Bull$0.7650
Price $0.5630 · Upside +8.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham)$0.4700$0.7200$0.900052
All 1 models by family
Asset-Based
NCAV (Graham)$0.4700$0.7200$0.900052
The fair value above starts from this blend and is adjusted for dilution from new shares.
In the last 6 months, 5 officers or directors sold shares worth $176,540 and none bought.
SaleRobert D. Allen IIIChief Scientific Officer2× since Feb 17, 2026: 75,303 shares, avg. $1.17$87,855Aug 18, 202610b5-1 plan
SaleJill AndersenChief Legal Officer, Secretary2× since Feb 17, 2026: 135,672 shares, avg. $1.17$158,288Aug 18, 202610b5-1 plan
SaleWilliam E. DukeChief Financial Officer2× since Feb 17, 2026: 81,407 shares, avg. $1.17$94,977Aug 18, 202610b5-1 plan
SaleJulie GreenChief Human Resources Officer2× since Feb 17, 2026: 81,407 shares, avg. $1.17$94,977Aug 18, 202610b5-1 plan
SaleTimothy Edward LeeChief Commercial Officer2× since Feb 17, 2026: 81,407 shares, avg. $1.17$94,977Aug 18, 202610b5-1 plan
BuyKevin F McLaughlinDirector50,000 shares at $2.50$125,000Nov 19, 2025
Plus 5 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.29/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score41 · Below median
Fair Value upside+8.7% · Top 25%
Profitability
Return on assets−19.0% · Below median
Net margin (12 months)−183.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)21.2% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Invivyd Inc. Fair Value". https://www.fairvalue-calculator.com/stock/IVVD
Frequently asked questions
Is Invivyd Inc. (IVVD) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $0.6120 versus a price of $0.5630, about +9% upside (fairly valued).
What is the fair value of IVVD?
Our model-based fair value for Invivyd Inc. is $0.6120 (as of Nov 8, 2026), built from audited fundamentals. The current price: $0.5630.
What is the quality score of IVVD?
Invivyd Inc. has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Invivyd Inc. (IVVD)?
Our model-based price target is the fair value of $0.6120 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario $0.3995, optimistic scenario $0.7650. It is a calculation from audited fundamentals, not an analyst target.
What is the Invivyd Inc. stock forecast for 2026?
Our models put fair value at $0.6120, about +9% upside versus a price of $0.5630 (fairly valued). Cautious scenario $0.3995, optimistic scenario $0.7650. The calculation is refreshed regularly with new filings.
What is the revenue of Invivyd Inc. (IVVD)?
Invivyd Inc. reported trailing-twelve-month revenue of about $58.4M (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Invivyd Inc. (IVVD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Invivyd Inc. it is $0.6120 per share (as of Nov 8, 2026), against a price of $0.5630. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Invivyd Inc. stock overvalued or undervalued in 2026?
As of Nov 8, 2026, IVVD trades below its calculated fair value: price $0.5630, fair value $0.6120, a gap of about +9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IVVD?
No. The price is what the market pays today ($0.5630); the fair value is what the company's own numbers justify ($0.6120). For Invivyd Inc. the two are $0.0490 per share apart. That gap is exactly why we show both numbers side by side.
How much is Invivyd Inc. worth?
The market values Invivyd Inc. at about $180M (market capitalisation, as of Nov 8, 2026). Per share that is $0.5630; our models calculate a fair value of $0.6120 per share.
What do the bullish and bearish scenarios say about IVVD?
Our models span a range for Invivyd Inc.: cautious scenario $0.3995, base $0.6120, optimistic $0.7650 per share (as of Nov 8, 2026, price $0.5630). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Invivyd Inc. (IVVD)?
Balance-sheet figures for Invivyd Inc. (as of Nov 8, 2026): return on equity −95.9%. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is IVVD from its 52-week high?
Invivyd Inc. trades at $0.5630, about 80% below its 52-week high of $2.88 and 5% above the low of $0.5350 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6120 is for.
Which stocks are comparable to Invivyd Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Invivyd Inc. stock attractive at the current price?
The data as of Nov 8, 2026: price $0.5630, calculated fair value $0.6120 (+9%), Quality Score 41/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IVVD calculated?
We run Invivyd Inc. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $0.6120 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Invivyd Inc. currently trades 8% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Invivyd Inc. (IVVD)?
The closing price on Nov 6, 2026 was $0.5630. Our model-based fair value is $0.6120, about +9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Invivyd Inc. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($0.3995 to $0.7650) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Invivyd Inc.
How large is the market capitalisation of Invivyd Inc. (IVVD)?
The market capitalisation of Invivyd Inc. is $180M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Invivyd Inc. (IVVD)?
The price-to-sales ratio of Invivyd Inc. is 2.84 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Invivyd Inc. (IVVD)?
Earnings per share at Invivyd Inc. are $−0.3300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Invivyd Inc. (IVVD)?
The net margin of Invivyd Inc. is −98.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Invivyd Inc. (IVVD)?
The return on equity (ROE) of Invivyd Inc. is −95.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Invivyd Inc. (IVVD)?
On an EBIT basis the return on assets of Invivyd Inc. is −70.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Invivyd Inc. (IVVD)?
The operating margin of Invivyd Inc. is −321% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Invivyd Inc. (IVVD)?
Revenue at Invivyd Inc. is growing +21.2% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Invivyd Inc. (IVVD) generate?
The free cash flow of Invivyd Inc. is −$58.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Invivyd Inc. (IVVD) hold?
Invivyd Inc. holds more cash than debt, $224M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Invivyd Inc. in the live analysis
One click puts Invivyd Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026
